S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sorafenib works in treating patients with
unresectable or metastatic gallbladder cancer or cholangiocarcinoma. Sorafenib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking
blood flow to the tumor